RE:RE:RE:RE:So now they have a significant trial in TurkeyHere is my best guess. MedX has stated they have a number of trials in the offing. They seem to have sorted out how to go to market. Your question is not quite framed properly and therfore hard to answer. Let me reframe it, right now MedX has a few pilots/trials running in a number of countries.What if in the next quarter they had 20 trials in progress ands a number completed and doing a full roll-out? You are talkng about 1,000's of scopes being deployed and an endless number coming on-line.
The market will not wait until all of the scopes are deployed it will start to assume a percentage of succesful trials and rollouts and ascribe a discounted number to the total potential sales. Each scope will represent a number of scans a day. Some will be in high traffic areas some in low traffic areas. Eventually there will be a large enough sample set to have some pretty accurate forcast numbers.
So to answer your question we are just starting to see a trend line we will not know with any certainty for another quarter or two how quickly the revenue will ramp.
We do know that they have made some progress in the European market and Canada,we will have to wait and see how quickly this trend continues.
We know the company is now deploying scopes and that the market is diverse and accepting the DermSecure platform and the share price is not giving these developments any value.